Once-weekly insulin study for type 2 diabetes
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests whether switching from daily basal insulin to once-weekly insulin icodec improves blood sugar control, treatment satisfaction, and how well people stick with the new insulin. It may be a good option if you have type 2 diabetes and are already using a daily basal insulin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with type 2 diabetes for at least 1 year.
- You have been taking a daily basal insulin (once or twice a day) for at least 6 months.
- You are not currently using mealtime (bolus) insulin for 14 days or more in the last 3 months.
- You have not used once-weekly insulin before.
- You are willing and able to participate and give consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well once-weekly insulin icodec controls blood sugar and improves quality of life for people with type 2 diabetes who currently take daily insulin injections. You'll switch from your daily insulin to a once-weekly injection and the study will track your blood sugar control, treatment satisfaction, and how well you stick with the new schedule.
This study tests a new once-weekly insulin shot (icodec) compared to daily long-acting insulins for people with type 2 diabetes whose blood sugar is not well controlled on their current non-insulin medications.
This study tests an investigational injectable medicine (IN-B00009) to see how well it controls blood sugar in adults with type 2 diabetes that is not well managed by diet and exercise alone. If you qualify, you may receive the study drug and will be monitored closely to see if it helps lower your blood sugar safely.
This study tests a once-weekly injection (HDM1005) to see if it improves blood sugar control in people with type 2 diabetes who are already taking metformin alone or with an SGLT2 inhibitor. It may help lower your A1C levels and manage your weight.
This study tests a new once-weekly injectable medication (HDM1005) for people with type 2 diabetes whose blood sugar is not well controlled by diet and exercise or metformin alone. It aims to help lower blood sugar and may also support weight loss.
This study tests an experimental medicine called RGB-5088 for people with type 2 diabetes who are already using insulin. The goal is to see if it can safely improve blood sugar control when added to your current diabetes management.
Hear when a new Diabetes Mellitus, Type 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.